Compare HNI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HNI | MLYS |
|---|---|---|
| Founded | 1944 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 1994 | 2023 |
| Metric | HNI | MLYS |
|---|---|---|
| Price | $36.59 | $22.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $70.00 | $48.67 |
| AVG Volume (30 Days) | 867.3K | ★ 1.1M |
| Earning Date | 05-06-2026 | 03-12-2026 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $2,839,000,000.00 | N/A |
| Revenue This Year | $117.47 | N/A |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | $30.52 | ★ N/A |
| Revenue Growth | ★ 12.37 | N/A |
| 52 Week Low | $33.72 | $10.44 |
| 52 Week High | $53.29 | $47.65 |
| Indicator | HNI | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 29.60 | 29.08 |
| Support Level | N/A | $13.42 |
| Resistance Level | $47.68 | $31.09 |
| Average True Range (ATR) | 1.46 | 1.72 |
| MACD | -0.42 | -0.27 |
| Stochastic Oscillator | 30.32 | 5.24 |
HNI Corp is a provider of commercial furnishings and hearth products. Its two reportable segments are workplace furnishings and residential building products. The workplace furnishings segment includes furniture systems, seating, storage, tables, architectural products, ancillary products, and hospitality products. The residential building products segment includes various gas, wood, electric, and pellet-fueled fireplaces, inserts, stoves, facings, outdoor fire pits and fire tables, and accessories. The company's products are sold through independent dealers, distributors, eCommerce retailers, wholesalers, and retail outlets. A majority of the firm's revenue is generated from the Workplace furnishings segment. Geographically, it operates in the United States.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.